NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

NADPH Oxidase Correction in mRNA transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Institute of Allergy and Infectious Diseases (NIAID)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male
Min Age: 18 Years
Max Age: 75 Years

Referral Letter Required


Population Exclusion(s)



Primary Immune Deficiency;
systemic infection;
autologous transfusion;

Recruitment Keyword(s)



Chronic Granulomatous Disease;

Investigational Drug(s)


Investigational Device(s)



Biological/Vaccine: gp91 Grans

Supporting Site

National Institute of Allergy and Infectious Diseases


CGD is caused by a gene mutation. For people with CGD, their cells cannot kill germs well, so they can get frequent or life-threatening infections. Researchers want to see if a new procedure can help a person s cells kill germs for a short time. It uses messenger RNA (mRNA) to deliver correct instructions for the gene mutation to the cells.


To test a procedure in which mRNA is added to a person s blood cells.


Males aged 18-75 with CGD with a mutation in the gene that makes the protein gp91phox.


Participants will be screened with:

Medical history

Physical exam

Blood and urine tests

Swab to test for strep throat

Some screening tests will be repeated during the study.

Participants will be admitted to the NIH Clinical Center hospital for at least 7 days. They will have apheresis. For this, a medicine is injected under their skin to prepare their white blood cells for collection. An IV line is placed into an arm vein. Blood goes through the IV line into a machine that divides whole blood into red blood cells, plasma, and white blood cells. The white blood cells are removed, and the rest of the blood is returned to the participant through an IV line in their other arm. The next day, they will get their mRNA-corrected cells via IV. They will be monitored for 3 more days.

After discharge, participants will keep a symptom diary. They will be contacted weekly for one month, and then once a month. They will have a follow-up visit 3 months after the infusion.

--Back to Top--



Individuals must meet all of the following criteria to be eligible for study participation:

-Males aged 18 to 75 years

-CGD confirmed by DHR and gp91phox-deficiency subtype confirmed by protein analysis and/or genetic sequencing

-Has a physician at home for follow-up care

-Able to provide informed consent

-For men who engage in activities that can result in pregnancy, agree to use contraception when engaging in sexual activities that can result in pregnancy. Contraception must be used from screening through 3 months after the gp91-Grans infusion. Acceptable methods of contraception include the following:

--Hormonal contraception

--Male or female condom


Individuals meeting any of the following criteria will be excluded from study participation:

-Evidence of moderate to severe systemic infections as defined by any of the following:

--Fevers >=39 (Infinite)C within 3 days of treatment.

--Absolute neutrophil count (ANC) >12,000/microliter at screening (some CGD patients may chronically have ANC higher than the upper limit of normal value and not have a systemic infection).

--Standard clinical diagnosis (by any imaging technology) of pneumonia, liver abscess, or other deep tissue abscess (other than chronic anal fissures or fistula or superficial skin or subcutaneous infections, which are allowable for this trial) at screening.

--Positive blood culture within 2 weeks of treatment.

-Receipt of a high-dose steroid, equivalent to >1 mg/kg/day of prednisone, within 30 days of screening. There is a high percentage of CGD patients with inflammatory bowel disease on >0.5 mg/kg/day maintenance prednisone.

-Current or history of stage 4 chronic kidney disease or estimated glomerular filtration rate

[eGFR] <30 mL/min/1.73 m^2 within 90 days of baseline.

-Unstable diabetes mellitus with hemoglobin A1c >7.0% and fasting serum glucose >200 mg/dL at screening.

-Current or history of heart failure stage D as defined by the American College of Cardiology Foundation/American Heart Association guidelines.

-History of arrhythmias that are symptomatic and deemed clinically unsafe for participation by NIH CC Cardiology consultation.

-Current or history of invasive cancers that require chemotherapy within 5 years of screening.

-Evidence of urinary tract infection at screening.

-Evidence of streptococcal pharyngitis at screening.

-Active hepatitis B, C, or HIV infections at screening.

-Unstable hypertension requiring addition of new anti-hypertensives within 2 weeks of screening.

-Impaired renal function that is unstable, with serum creatinine >3.0 mg/dL and rising.

-Serum transaminases and bilirubin that are >3 x the upper limit of normal.

-Electrocardiogram abnormalities indicative of acute myocardial injury, or arrhythmias that presents anesthetic risks, at screening.

-Anemia with hemoglobin <8 g/dL (transfusions to correct anemia permitted).

-Thrombocytopenia (platelets <50 x10^9 cells/L) (platelet transfusions to correct thrombocytopenia permitted).

-Profound thrombocytopenia (platelet counts <10,000/microliter) that is not reversible with platelet transfusions.

-Abnormal prothrombin time/partial thromboplastin time (PT/PTT) values outside the ranges accepted at the NIH CC that are not corrected or that cannot be attributed to presence of Lupus anticoagulant (commonly found in CGD patients).

-Inherited bleeding disorder that precludes line placement.

-Severe oxygen-dependent pulmonary disease that increases risks of procedures that may require sedation.

-History of or current evidence of alcohol or illicit drug abuse or dependence.

-Participation in a clinical protocol that includes an intervention that, in the opinion of the investigator, may affect the results of the current study.

Subjects will be selected in an equitable manner from the available pool of potentially eligible individuals, without regard to factors such as gender, race, ethnicity, socioeconomic status, etc, except for age and sex.

--Back to Top--


--Back to Top--


Principal Investigator

Referral Contact

For more information:

Suk S. De Ravin, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
NIHBC 10 - CRC BG RM 5-3816
(301) 496-6772

Joanna L. Peterson
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health
Building 10
Room 13N254
10 Center Drive
Bethesda, Maryland 20892
(240) 292-4291

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: TTY Users Dial 7-1-1

Clinical Trials Number:


--Back to Top--